摘要
No AccessJournal of UrologyCLINICAL UROLOGY: Letters to the Editor1 Oct 2002Re: Diethylstilbesterol Revisited: Androgen Deprivation, Osteoporosis and Prostate Cancer W.Reid Pitts W.Reid PittsW.Reid Pitts More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64498-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Re: Diethylstilbesterol Revisited: Androgen Deprivation, Osteoporosis and Prostate Cancer." The Journal of Urology, 168(4 Part 1), pp. 1506–1507 115 E. 61st St.11th FloorNew York, New York 10021© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byPitts W (2018) Re: Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate CancerJournal of Urology, VOL. 170, NO. 6, (2392-2393), Online publication date: 1-Dec-2003. (2018) Re: Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate CancerJournal of Urology, VOL. 170, NO. 6, (2392-2394), Online publication date: 1-Dec-2003.Pitts W (2018) Re: Enhancement of Diethylstilbestrol Induced Cytotoxicity by bcl-2 Antisense Oligodeoxynucleotides and a Glutathione Depletor for Prostate CancerJournal of Urology, VOL. 170, NO. 5, (1954-1954), Online publication date: 1-Nov-2003. (2018) Re: Enhancement of Diethylstilbestrol Induced Cytotoxicity by bcl-2 Antisense Oligodeoxynucleotides and a Glutathione Depletor for Prostate Cancer: Reply by AuthorsJournal of Urology, VOL. 170, NO. 5, (1954-1955), Online publication date: 1-Nov-2003. Volume 168Issue 4 Part 1October 2002Page: 1506-1507 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.MetricsAuthor Information W.Reid Pitts More articles by this author Expand All Advertisement PDF downloadLoading ...